SCHEMBL4457259

SCHEMBL4457259

Nc1ccc(-c2c[nH]c(COc3ccccc3)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
MAPT P10636 4/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
GAA P10253 1/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
XDH P47989 2/20 0.43
NPC1 O15118 6/20 0.43
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
GLA P06280 1/20 0.39
KCNH2 Q12809 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3270671 0.95 MAOA (0.46) RAB9ASMN1; SMN2MAPTL3MBTL1GAA
Hydrochloric Acid SCHEMBL4461345 0.94 XDH (0.45) RAB9ASMN1; SMN2MAPTL3MBTL1GAA
SCHEMBL4466562 0.90 RAB9A (0.45) RAB9ASMN1; SMN2MAPTL3MBTL1MAOA
SCHEMBL5750527 0.87 LMNA (0.44) RAB9ASMN1; SMN2MAPTL3MBTL1XDH
SCHEMBL4686964 0.87 MCL1 (0.46) RAB9ASMN1; SMN2MAPTL3MBTL1XDH
SCHEMBL5750522 0.86 RAB9A (0.43) RAB9ASMN1; SMN2MAPTL3MBTL1XDH
SCHEMBL4680896 0.85 MAOB (0.49) RAB9AMAPTMAOAMAOBXDH
SCHEMBL4458347 0.84 VCP (0.42) RAB9ASMN1; SMN2MAPTL3MBTL1XDH
SCHEMBL4468971 0.84 XDH (0.43) RAB9ASMN1; SMN2XDHNPC1TP53
Hydrochloric Acid SCHEMBL4459819 0.84 MAOB (0.48) RAB9AMAPTMAOAMAOBXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed
EP-1638943-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-03-29 EP disclosed
WO-2004106307-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 RAB9A 2552/4885SMN1; SMN2 4745/4885MAPT 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.